Screener
Castle Biosciences CSTL CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from maturities of marketable investment securities | 39,100 | 36,300 |
| Purchases of debt securities classified as held-to-maturity | — | (5,569) |
| Proceeds from sale of equity securities | 2,681 | — |
| Purchases of property and equipment | (12,455) | (4,740) |
| Proceeds from sale of property and equipment | 7 | 9 |
| Net cash used in investing activities | (25,803) | (22,431) |
| FINANCING ACTIVITIES | ||
| Proceeds from exercise of common stock options | 322 | 18 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's capex?
- Castle Biosciences (CSTL) reported capex of $12.46M in Q1 2026.
- How has Castle Biosciences's capex changed year-over-year?
- Castle Biosciences's capex increased by 162.8% year-over-year, from $4.74M to $12.46M.
- What is the long-term trend for Castle Biosciences's capex?
- Over 4 years (2021 to 2025), Castle Biosciences's capex has grown at a 79.3% compound annual growth rate (CAGR), from $3.48M to $36.02M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Castle Biosciences's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude